PVC Clinical Trials & Post-Marketing Surveillance 1 — Questions and Answers
Question 1: What is the primary goal of pharmacovigilance in clinical trials?
- To analyze drug sales
- To obtain regulatory approval faster
- To monitor safety of investigational drugs (Correct answer)
- To promote new medicines
Correct answer: To monitor safety of investigational drugs
During clinical trials, pharmacovigilance aims to ensure the early detection of safety signals and protect trial participants.
Question 2: Which phase of clinical trials focuses most on assessing a drug's safety profile?
- Phase I (Correct answer)
- Phase II
- Phase III
- Phase IV
Correct answer: Phase I
Phase I trials are designed to assess the safety, tolerability, and pharmacokinetics of a drug in healthy volunteers or patients.
Question 3: Which report is essential for post-marketing safety surveillance?
- Case Study Report
- Periodic Safety Update Report (PSUR) (Correct answer)
- Site Monitoring Visit Report
- Informed Consent Form
Correct answer: Periodic Safety Update Report (PSUR)
Periodic Safety Update Reports (PSURs) are submitted after a drug is approved to monitor its benefit-risk profile in the general population.
Question 4: Which regulatory document guides safety reporting during clinical trials?
- ICH E6
- ICH Q10
- ICH E2A (Correct answer)
- ICH M4
Correct answer: ICH E2A
ICH E2A provides guidance for clinical safety data management, particularly the reporting of adverse drug reactions in trials.
Question 5: What is a key purpose of post-marketing surveillance?
- To conduct marketing campaigns
- To replace clinical trials
- To evaluate manufacturing cost
- To detect adverse events in real-world use (Correct answer)
Correct answer: To detect adverse events in real-world use
Post-marketing surveillance ensures ongoing monitoring of drug safety and helps detect rare or long-term adverse effects not found in trials.
Question 6: Which of the following best describes a spontaneous report?
- A formal report from a clinical trial
- A mandatory report submitted by a sponsor
- An unsolicited report of an adverse event (Correct answer)
- An internal audit document
Correct answer: An unsolicited report of an adverse event
A spontaneous report is an unsolicited communication by a healthcare professional or consumer to a regulatory authority or manufacturer.
PVC Clinical Trials & Post-Marketing Surveillance 1
What is the primary goal of pharmacovigilance in clinical trials?